New FDA requirements could provide opportunities for Genmab, CEO says

Genmab CEO Jan van de Winkel thinks the FDA’s new project, Optimus, could be good for the firm, as it will require more work do be done to find the optimal dosage of cancer treatments.
Photo: PR / Genmab
Photo: PR / Genmab
by marketwire, translated by catherine brett

New guidelines from the US Food and Drug Administration (FDA) concerning the development of cancer treatments could have a big impact on the sector, says Genmab’s CEO Jan van de Winkel.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading